COLOFAC 135 MG TABLETS 135 Milligram Tablets

Χώρα: Ιρλανδία

Γλώσσα: Αγγλικά

Πηγή: HPRA (Health Products Regulatory Authority)

Δραστική ουσία:

MEBEVERINE HYDROCHLORIDE

Διαθέσιμο από:

Abbott Healthcare Products Ltd

INN (Διεθνής Όνομα):

MEBEVERINE HYDROCHLORIDE

Δοσολογία:

135 Milligram

Φαρμακοτεχνική μορφή:

Tablets

Τρόπος διάθεσης:

Product subject to prescription which may be renewed (B)

Καθεστώς αδειοδότησης:

Authorised

Ημερομηνία της άδειας:

0000-00-00

Φύλλο οδηγιών χρήσης

PACKAGE LEAFLET: INFORMATION FOR THE USER 

COLOFAC 135 MG TABLETS 
Mebeverine hydrochloride 

READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT 
CONTAINS IMPORTANT INFORMATION FOR YOU. 
• Keep this leaflet. You may need to read it again. 
• If you have any further questions, ask your doctor or
pharmacist. 
• This medicine has been prescribed for you only. Do not pass it
on to others. It may 
harm them, even if their signs of illness are the same as yours.If
you get any side effects , 
talk to your doctor or pharmacist.  This includes any possible side
effects not listed in this 
leaflet.  
WHAT IS IN THIS LEAFLET 
1. What Colofac is and what it is used for 
2. What you need to know before you take Colofac 
3. How to take Colofac 
4. Possible side effects 
5. How to store Colofac 
6. Contents of the pack and other information 

1. WHAT COLOFAC IS AND WHAT IT IS USED FOR 
WHAT COLOFAC IS 
The name of your medicine is Colofac 135 mg tablets_ _(called
Colofac in this leaflet). 
Colofac contains a medicine called mebeverine hydrochloride. This
belongs to a group of 
medicines called antispasmodics, which act on your gut or
intestine. 
The intestine is a long muscular tube which food passes down so it
can be digested. If the 
intestine goes into spasm and squeezes too tightly, you get pain.
This medicine works by 
relieving the spasm and pain. 
WHAT COLOFAC IS USED FOR 
Colofac is used to relieve the symptoms of irritable bowel syndrome
(IBS). These 
symptoms vary from person to person but can include: 
• stomach pain and cramps 
• feeling bloated and having wind 
• diarrhoea, constipation or a combination of both 
• small, hard, pellet-like or ribbon-like stools (faeces). 
Colofac is also used to relieve cramps and pain in your stomach or gut
caused by other 
medical conditions. 

2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE COLOFAC 
DO NOT TAKE COLOFAC 
• if you are allergic  to mebeverine hydroch

Αρχείο Π.Χ.Π.

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Colofac 135 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each coated tablet contains mebeverine hydrochloride 135mg
Excipients: also includes Lactose monohydrate 97.0 mg per tablet and Sucrose 79.0 mg per tablet.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Coated Tablet.
White, circular, sugar coated tablet.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For use in the management of irritable bowel syndrome, (particularly gastrointestinal spasm).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
For oral use.
The coated tablets should be swallowed with a sufficient amount of water (at least 100 ml water). They should not be
chewed because of the unpleasant taste.
Adults and children over 10 years:
One tablet three times a day preferably 20 minutes before meals.
Duration of use is not limited. However, after a period of several weeks when the desired effect has been obtained, the
dosage may be gradually reduced.
In case of missed dose(s), the patient should continue with the next dose as prescribed; do not take the missed dose(s)
in addition to the regular dose.
Children under 10 years:
Colofac should not be used in children aged 3 years and younger as no clinical data are available. For children from 3-
10 years Colofac 135mg tablets should not be used due to the high content of the active substance.
Special Population
No posology studies in elderly, renal and/or hepatic impaired patients have been performed. No specific risk for
elderly, renal and/or hepatic impaired patients could be identified from available post-marketing data. No dosage
adjustment is deemed necessary in elderly, renal and/or hepatic impaired patients.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active